Buprenorphine Hcl Tablet
Product Images NDC 31722-871

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Buprenorphine Hcl (NDC 31722-871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 mg 30s Count (01 30)

2 mg 30s Count (01 30)
This text provides information about Buprenorphine Sublingual Tablets in 2 mg strength. It emphasizes the importance of keeping the medication out of reach of children and the need for emergency medical care if accidentally ingested by children. The text also includes details on dosage, storage instructions, and mentions where to find the Medication Guide for further information. The tablets are manufactured by Ascent Pharmaceuticals, Inc. and distributed by Camber Pharmaceuticals, Inc.*
FDA Label Image

8 mg 30s Count (02 30)

8 mg 30s Count (02 30)
This is a description of buprenorphine sublingual tablets manufactured by Ascent Pharmaceuticals for Camber Pharmaceuticals. The medication guide advises dispensing it to each patient and mentions the need for emergency medical care if children accidentally take it. Each tablet contains 8.64 mg of buprenorphine HCl, USP equivalent to 8 mg of buprenorphine base. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It is important to keep the tablets in a safe place out of reach of children. More information can be found in the medication guide provided at camberpharma.com/medication-guides.*
FDA Label Image

Mg1 (1)

Mg1 (1)
This text outlines symptoms one may experience when feeling unwell or in need of medical attention. These symptoms include feeling faint, dizzy, confused, sleepy, uncoordinated, with blurred vision, slurred speech, slow breathing, and impaired cognitive function. These signs may indicate a serious health issue and require immediate medical assistance.*
FDA Label Image

17 (17)

17 (17)
This text discusses the importance of patient access to naloxone for the emergency treatment of opioid overdose. It emphasizes educating patients and caregivers on how to recognize signs of an overdose, obtaining naloxone through various channels such as prescription or community-based programs, and the temporary effects of naloxone. It also highlights the necessity of calling 911 or seeking emergency medical help even after administering naloxone and the potential need for repeat administration in certain cases. Advice is provided on how to treat an opioid overdose with naloxone, informing family and friends about naloxone's location, and reading educational materials beforehand to be prepared for an emergency.*
FDA Label Image

Mg2 (2)

Mg2 (2)
This text seems to describe various health issues related to tooth problems, enlarged prostate, head injury, cavities, trouble breathing, lung problems, urinary problems, mental health problems, spinal curvature affecting organs, and conditions such as Addison's disease and alcoholism. It highlights potential connections between these conditions and the mentioned health concerns.*
FDA Label Image

Mg3 (3)

Mg3 (3)
This text mentions symptoms to watch out for related to liver problems, including yellow skin or eyes, dark urine, right-sided stomach pain, light-colored stools, and loss of appetite. These symptoms could indicate jaundice or other liver issues. It is important to seek medical attention if experiencing these symptoms.*
FDA Label Image

Mg4 (4)

Mg4 (4)
This text appears to be a list of symptoms related to possible health conditions. It mentions symptoms like shaking, sweating more than normal, feeling hot or cold more than normal, runny nose, watery eyes, goosebumps, diarrhea, vomiting, and muscle aches. These symptoms may indicate a range of illnesses or conditions and may require medical attention.*
FDA Label Image

Mg5 (5)

Mg5 (5)
This text mentions common symptoms such as headache, pain, nausea, increased sweating, vomiting, and insomnia. These symptoms could indicate various health conditions and may require medical attention.*
FDA Label Image

Chem-fig (Bup HCl Chem Fig)

FDA Label Image

Ifu-image (Ifu Image)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.